Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Smartwatch-Guided Secondary Prevention After Stroke (WATCH-STEP)

5 juni 2026 uppdaterad av: University Hospital, Brest

WATCH-STEP : Pilot Trial: Smartwatch-Guided Secondary Prevention After Stroke Randomized Trial of Nurse-led Program With Active vs Passive Smartwatch in Minor Stroke. A Randomized Controlled Trial Evaluating a Nurse-led Secondary Prevention and Physical Activity Program Supported by Either an Active Smartwatch (Structured Feedback) or Passive Smartwatch in Patients With Minor Stroke.

After a first stroke or transient ischemic attack (TIA), the risk of recurrence is high in the weeks and months following the initial event. There are several modifiable risk factors that can reduce this risk, such as blood pressure, diet, physical activity, and smoking. Many stroke patients (NIHSS < 5) have a low daily step count during the early recovery period, despite a good functional prognosis.

Active smartwatches provide real-time feedback, track progress, and set personalized walking goals, thereby boosting motivation and adherence to physical activity recommendations.

The combination of advice provided by nurses and active behavioral coaching supported by a smartwatch, compared to passive monitoring, could significantly increase daily step counts over a 12-week period. The results of this research will help guide future large-scale secondary prevention strategies integrating digital health and structured nursing support.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Detaljerad beskrivning

To meet the study's objectives, 50 patients who have recently suffered a stroke or a transient ischemic attack (TIA) (< 30 days) will be recruited at Brest University Hospital.

Participation in this study will last 12 weeks. It consists of 3 visits, described below:

=> Visit #1: Enrollment (hospital)

Enrollment will take place during a routine hospital visit. The investigator will obtain the patient's written consent. Randomization will then be performed to assign the patient to a group ("active" or "passive" watch).

For all patients ("active" and "passive" watch groups):

  • Program led by nurses, conducted as part of routine care following a recent ischemic stroke or TIA (secondary prevention).
  • Issuance of a smartwatch and a smartphone
  • Data collection (sociodemographic information, medical history, current treatments, risk factors)
  • Questionnaires
  • Clinical examination, neurological examination, and blood draw.

For patients in the "passive" smartwatch group:

o The smartwatch will collect data passively, without notifications.

For patients in the "active" smartwatch group:

  • Setting daily step goals and assessing potential obstacles

  • Scheduling regular calls (twice a week) for the duration of the study.

    • Visit #2: Phone call

For all patients (both "active" and "passive" watch):

  • Phone contact to collect data on changes in risk factors and the occurrence of events of interest (stroke, TIA, and cardiovascular events).

  • Questionnaires

    • Visit #3: End of study (hospital)

The end-of-study visit will take place at the hospital during a scheduled routine care appointment:

  • Assessment with a nurse as part of the secondary prevention program (routine care)
  • Data collection (risk factors)
  • Questionnaires
  • Clinical examination, neurological examination, and blood draw
  • Return of the smartwatch and smartphone

Studietyp

Interventionell

Inskrivning (Beräknad)

50

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Age ≤ 40-75
  • Patients with recent minor ischemic stroke or TIA, initial NIHSS ≤5 (< 30 days)
  • mRS ≤2 before stroke and on discharge
  • Patient with Wifi access (for data transmission)
  • Able to understand smartwatch instructions
  • Written informed consent
  • Ambulatory ≥10 meters without assistance and without walking aid
  • Expected to live at home during the study period.

Exclusion Criteria:

  • Patients with transient neurological deficits resolving within one hour and normal brain imaging will be excluded
  • Not affiliated to social security
  • Patient under legal protection or deprived of liberty by a judicial or administrative decision
  • Patient whose follow-up will be impossible
  • Cognitive impairment interfering with participation (e.g., MoCA <20).
  • Unstable cardiac conditions preventing walking goals.
  • Major visual or upper limb impairment preventing use of the smartwatch.
  • Life expectancy <1 year.
  • Already highly active (>10,000 steps/day, or about 1.5 hours of walking).
  • Participation in competing interventional trials.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: "Passive" Smartwatch arm
  • Smartwatch collects step and wear-time data passively.
  • Participants do not receive daily goals, structured prompts, or real-time feedback regarding progress.
  • Nurses provide general advice but do not review detailed step graphs.
  • Data used only for endpoint assessment at M3.
Experimentell: "Active" Smartwatch arm
  • Smartwatch provides real-time structured feedback, including daily step counts, a visual progress bar, and automated prompts.
  • Research technician review step graphs during tele-visits, highlighting high/low activity days, barriers, and facilitators personalized daily step goals (twice a week) defined as +15-20% above baseline will be adjusted by Research technician based on progress and symptoms.
  • Goals increased by +10% if ≥4/7 days meet targets; maintained or decreased if symptomatic or not meeting goals.
Övrig: Smartwatch-Guided Secondary Prevention after Stroke
Setting daily walking goals, assessing obstacles Regular phone calls (twice a week) to review progress, adjust goals, and provide support

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To determine whether the addition of an active smartwatch providing structured feedback to a nurse-led activity program produces a significantly greater increase in daily step count over 12 weeks compared with the same program paired with a passive smart
Tidsram: Week 12
Difference in steps/day at 12 weeks between both arms (average of the final 14 valid days) (target Δ ≥ 1500)
Week 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To evaluate feasibility to smartwatch wear
Tidsram: Week 6 and Week 12
Wear-time adherence at W6 and W12
Week 6 and Week 12
To evaluate adherence to smartwatch wear
Tidsram: Week 6 and Week 12
System Usability Scale (SUS) at W6 and W12
Week 6 and Week 12
To evaluate acceptability of digital feedback.
Tidsram: Week 6 and Week 12
TAM (technology Acceptance Model) at W6 and W12
Week 6 and Week 12
To assess the impact of active smartwatch feedback on sedentary time.
Tidsram: day 1 to week 12
Resting time (excluding sleep) at baseline, W6 and W12
day 1 to week 12
To assess the impact of active smartwatch feedback on gait-related activity patterns.
Tidsram: day 1 to week 12
gait performance metrics (data from the smartwatch)
day 1 to week 12
To assess the impact of active smartwatch feedback on blood pressure.
Tidsram: day 1 to week 12
Continuous mean SBP and DBP and time-in-range at baseline, W6 and W12
day 1 to week 12
To monitor falls
Tidsram: day 1 to week 12
Number of falls (collected continuously via the smartwatch) between baseline and W6 and between baseline and W12.
day 1 to week 12
To monitor cardiovascular events (atrial fibrillation, AF),
Tidsram: day 1 to week 12
Number of cardiovascular events between baseline and W12.
day 1 to week 12
To examine effects on quality of life
Tidsram: day 1 to week 12
Quality of life : physical and mental SF-36 auto-questionnaire scores at baseline, W6 and W12
day 1 to week 12
To examine effects on risk factors
Tidsram: Day 1, week 6 and week 12
LDL cholesterol, alcohol, tobacco, weight and waist circumference at baseline and W12
Day 1, week 6 and week 12
Recurrence and cardiovascular events
Tidsram: day 1 to week 12
Recurrent stroke or TIA or cardiovascular events at W6 and W12 and in case of alert or hospitalization
day 1 to week 12
To examine effects on fatigue
Tidsram: day 1 to week 12
Fatigue : FAS and MFIS auto-questionnaires scores at baseline, W6 and W12
day 1 to week 12
To examine effects on cognition
Tidsram: day 1 to week 12
Cognition : MoCA-short score at baseline, W6 and W12
day 1 to week 12
To examine effects on depression
Tidsram: day 1 to week 12
Mood : PHQ-2 auto-questionnaire score at baseline, W6 and W12
day 1 to week 12
To examine effects on sleep
Tidsram: day 1 to week 12
Sleep : efficiency and fragmentation at baseline, W6 and W12 and continuous
day 1 to week 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

University Hospital, Brest

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 september 2026

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

29 maj 2026

Först inskickad som uppfyllde QC-kriterierna

5 juni 2026

Första postat (Faktisk)

10 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 29BRC23.0208

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All collected data that underlie results in a publication

Tidsram för IPD-delning

Data will be available after the publication of result and ending fifteen years following the last visit of the last patient

Kriterier för IPD Sharing Access

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera